Page 6 - Rare Genetics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda Announces New U S Corporate Social Responsibility (CSR) Program Partners

FY22 Investment Brings Program Total to Nearly $40 Million, Adding 21 New Grant Partners Company Continues to Improve Equity Among Under-Resourced Communities Focusing on Areas of Health,. | April 3, 2023

United statesSan diego riverCharles riverSan diegoLos angelesJulie kimPower of outdoor learning programWellness programCultural meals programFarming instituteTeaching instituteSan diego river park foundationDimock center partnershipAtlanta community food bankMeals distribution programFamily farm share program

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Takeda announced that its Board of Directors today decided that it will propose a new candidate for independent external director at the 147th Ordinary Meeting of Shareholders on June 28th, 2023.. | March 30, 2023

United statesHarvard universityJohn maraganoreMasami iijimaYoshiaki fujimoriConstantine saroukosChristophe weberEmiko higashiKoji hatsukawaJean luc butelKimberlya reedSteven gillisMasato iwasakiMiki tsusakaOlivier bohuonMichel orsinger

Takeda Pharmaceutical (TAK) Announces Publication of Phase 4 Vedolizumab Study Results

Takeda Pharmaceutical (TAK) Announces Publication of Phase 4 Vedolizumab Study Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJun saitoMegan ostrowerMarcelo freireJohn cunninghamSimon travisFachinformation entyvioTakeda pharmaceutical company limitedKennedy instituteEuropean unionInternational mediaGlobal medical affairsExchange commissionUniversity of oxfordTakeda pharmaceutical companyNew england journal

Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine

−The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus. | March 30, 2023

United statesSimon travisJohn cunninghamFachinformation entyvioMarcelo freireExchange commissionGlobal medical affairsEuropean unionKennedy instituteUniversity of oxfordTakeda pharmaceutical company limitedNew england journalProfessor simon travisTranslational gastroenterology unitVice presidentTherapeutic area head

BioLife Plasma Services Opens its 200th Plasma Donation Center in the U S

Expansion Contributes to the Company s Efforts Toward a Sustainable Global Plasma Supply to Support the Needs of People who Depend on Life-Saving Plasma Therapies. . | March 27, 2023

United statesTori weberBiolife plasma servicesUs operations at biolife plasma servicesWest springfieldBiolife plasmaSpanish thisLife plasma servicesRare geneticsPlasma derived therapiesTakeda pharmaceutical company limited stock exchangePress releaseLasma 4502 jp3463000004